Navigation Links
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Date:6/8/2008

Oral presentation at international lymphoma conference shows investigational regimen resulted in 82 percent overall survival and 78

percent progression-free survival rates in patients receiving

radioimmunotherapy Confirmatory phase III clinical trial is presently being conducted in this

patient population

LUGANO, Switzerland, June 9 /PRNewswire-FirstCall/ -- In an oral presentation today at the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland, Paul A. Hamlin, M.D., of Memorial Sloan-Kettering Cancer Center, presented results of an investigator-sponsored trial of the investigational regimen consolidating rituximab-CHOP (R-CHOP) with 90Yttrium Ibritumomab Tiuxetan (Zevalin(R)) radioimmunotherapy in high risk, elderly patients with previously untreated high-intermediate and high risk diffuse large B-cell lymphoma (DLBCL). Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) markets Zevalin in the United States.

"In a high risk, elderly patient population with significant comorbidities, sequential R-CHOP followed by radioimmunotherapy resulted in excellent complete response and overall and progression-free survival rates," concluded Hamlin. "This approach is now the focus of an international phase III study."

"Improvement of relapse-free survival in these patients is an important unmet need since the outcome is poor for patients who relapse with this disease and who cannot tolerate intensive salvage therapy and stem cell transplantation," said Jack W. Singer, M.D., Chief Medical Officer at CTI. "The survival data from this study are highly encouraging compared to historical data and provide the rationale for a registration-directed randomized trial of Zevalin consolidation in higher risk patients with DLBCL."

Results of the Study

Historical studies provided as background in the presentation indicate that approximately 50 perc
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
2. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
6. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
7. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
8. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
9. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)....J., Nov. 25 Pharmasset,...tical company committed to discovering, developing...fections, reported financial results for the fisca...2009 Pharmasset held $58.4 million in cash, cash e...eline Update and 2009 Highlights ,, RG7128 ,...
(Date:11/25/2009)...EACH, Fla., Nov. 25 For ..., especially the 27 million living with untreated ...appy, says audiologist Cindy Beyer. ,, Dr. Beye... one of America,s largest hearing care and hearin...g loss to stress, frustration, and social isolatio...
(Date:11/25/2009)...K, Nov. 25 Reportlinker.com announ... in its catalogue: ,, United States Dental Dev... http://www.reportlinker.com/p0158733/United-State...2015.html ,, United States Dental Devices Mark...,, This report is an essential source for in-de...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13Exposure to Common Pollutant in Womb Might Lower IQ 52093 1Exposure to Common Pollutant in Womb Might Lower IQ 52093 2Exposure to Common Pollutant in Womb Might Lower IQ 52093 3The Leukemia 26 Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 52091 1The Leukemia 26 Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 52091 2The Leukemia 26 Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 52091 3Mylan Declares Quarterly Preferred Stock Dividend 52089 1
...ta Include Results from Phase 1 Studies with Monoc...clinical Data Provide Further,Rationale for IL-9 I..., GAITHERSBURG, Md., May 24, 2007 /PRNewswire-Firs...entation of data,highlighting recent progress with...cluding results from two Phase 1 clinical,studies ...
...HAPEL HILL, N.C., May 25, 2007 /PRNewswire/ -- Wit...ceutical product at play,pharmaceutical firms nee...g clinical trial results early. Companies that mas...l gain a significant,advantage in the marketplace....Practices, LLC,successful companies create commun...
Other Medicine Technology:MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 2MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 3MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 4MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 5MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 6MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 7Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 2Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 3
(Date:11/28/2009)...ds gene variation believed to affect circadian rhy... News) -- New research suggests that an internal b... in the development of bipolar disorder in childre...of the genetic makeup of 152 children with bipolar...jor mood swings, and 140 children without the diso...
(Date:11/27/2009)..., BEDFORD, Mass., Nov. 27 /PRNewswire-FirstCall/...ny"), a supplier of precision technology products ... annual meeting of the Company,s shareholders has ...me and location of the meeting will be announced i...y received a requisition notice from Stephen Bersh...
(Date:11/27/2009)... Biotech firm Replikins Ltd. today...1 virus genomic data. It shows that the lethality...d. 4.5) during the virus,s current outbreak in the...s week of 2.0 (s.d. 0.1). The H1N1 infectivity cou... Boston (PRWEB) November 27, 2009 -- Biote...
(Date:11/27/2009)..., SAN FRANCISCO, Nov. 27 ...ed that Blair Lambert, CFO/COO, will present at th...held at the May Fair Hotel in London, England, on ..., To listen to a live broadcast of The Gymboree ...se log on to www.gymboree.com, click on "Our Compa...
(Date:11/27/2009)..., NEUILLY-SUR-SEINE, France, Nov. 27 /PRNewswir...rofessional cycling team dedicated to ethical spor... champions, announced today that it will become Te...ions Optical as a new sponsor of the team. Transit...f adaptive eyewear, offering the most advanced pho...
Breaking Medicine News(10 mins):Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:GSI Group Calls Shareholders Meeting 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3
...or lose it, principle at work, one expert says , ...uent sexual intercourse may cut down on a man,s ch...researchers report. , "This is the same as any oth...ssor of urology at UMDNJ New Jersey Medical School...
...., July 3 The Minnesota Nurses,Association (MNA) ...berg in,his candidacy for U.S. House of Representa...erg made it clear to us he shares a guiding princi...tee,Chair, Tom Kelly, RN. "With his unequivocal su...
... aimed at adults, but Australian team says these 3...HealthDay News) -- A series of tests that are the ...aste and smell have been developed by Australian r...rmined that most children ages 5 to 7 can identify...
...D In response to the global health crisis, 26 lea...tion movements in global health promotion, health ...t week on what should comprise the domains of core...l University of Ireland, Galway, who serves as the...
...Death Syndrome (SIDS) is a condition that unexpect...y healthy babies aged between a month and a year. ...Laboratory in Monterotondo, Italy, have developed ...odel, published in this week,s issue of Science ,...
... Renowned, Italian, orthopaedic surgeon, ... American Orthopaedic Society for Sports Medicine ...M’s Annual Meeting in Orlando. , ...rican Orthopaedic Society for Sports Medicine (AO...
Other Medicine News:Health News:Lots of Sex May Prevent Erectile Dysfunction 2Health News:Minnesota Nurses Association Endorses Elwyn Tinklenberg for Congress 2Health News:Accord on core competency, standards and quality assurance in health promotion and education 2Health News:New research sheds light on the molecular basis of crib death 2Health News:Paolo Aglietti, MD, President of the International Society of Knee Surgery and Arthroscopy, Inducted into Sports Medicine Hall of Fame 2
2100 Pulse Oximeter
Resolve® Immersion Oil
Immersion Oil, BTL
Immersion oil UV-transparent
Medicine Products: